From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
PKI 14-22 amide,myristoylated is a potent cAMP-dependent PKA inhibitor. PKI 14-22 amide,myristoylated reduces the IgG-mediated phagocytic response and also inhibits neutrophil adhesion .
PKI 14-22 amide,myristoylated TFA is a potent cAMP-dependent PKA inhibitor. PKI 14-22 amide,myristoylated TFA reduces the IgG-mediated phagocytic response and also inhibits neutrophil adhesion .
PKA Inhibitor Fragment (6-22) amide TFA is an inhibitor of cAMP-dependentprotein kinase A (PKA), with a Ki of 2.8 nM. PKA Inhibitor Fragment (6-22) amide TFA can significantly reverse antinociceptive tolerance in mice .
PKI (5-24),amide (IP20-amide) is a 20-residue peptide that corresponds to the active portion of the heat-stable inhibitor protein of cAMP-dependent protein kinase. PKI (5-24),amide is a potent cAMP-dependent protein kinase (PKA) (PKA) inhibitor with a Ki of 2.3 nM .
2-AHA-cAMP is an analogue of natural signal molecule cAMP and an activator of cAMP-dependent protein kinase. 2-AHA-cAMP has a free terminal primary amino group, which can be used for coupling to gels or fluorescent dyes .
PKA Inhibitor Fragment (6-22) amide is an inhibitor of cAMP-dependentprotein kinase A (PKA), with a Ki of 2.8 nM. PKA Inhibitor Fragment (6-22) amide can significantly reverse low-level morphine antinociceptive tolerance in mice .
8-HA-cAMP is a membrane-permeable cAMP analogue and an activator of cAMP-dependent protein kinase and PKA I. 8-HA-cAMP exerts metabolic stability towards mammalian cyclic nucleotide-responsive phosphodiesterases .
Sp-8-CPT-cAMPS, a cAMP analog, is a potent and selective activator of the cAMP-dependentprotein kinas A (PKA I and PKA II). Sp-8-CPT-cAMPS selects site A of RI compares to site A of RII by 153-fold and site B of RII compares to site B of RI by 59-fold .
8-Chloro-cAMP sodium is a cAMP analogue that induces growth arrest, and modulates cAMP-dependentPKA activity. 8-Chloro-cAMP sodium has anticancer activity .
2-Cl-cAMP is an analog of cAMP and a potent stimulator of cAMP-dependent protein kinases such as PKA type I and II. 2-Cl-cAMP can be used as starting material for cyclic nucleotides .
PKI(5-24) is a potent, competitive, and synthetic peptide inhibitor of PKA (cAMP-dependent protein kinase), with a Ki of 2.3 nM. PKI(5-24) corresponds to residues 5-24 in the naturally occurring heat-stable protein kinase inhibitor .
Rp-cAMPS, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependentPKA I and II (Kis of 12.5 μM and 4.5 μM, respectively) antagonist. Rp-cAMPS is resistant to hydrolysis by phosphodiesterases .
Rp-cAMPS sodium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependentPKA I and II (Kis of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS sodium salt is resistant to hydrolysis by phosphodiesterases .
6-Bn-cAMP is a site-selective activator of cAMP-dependent protein kinase (PKA) which does not activate Epac. 6-Bn-cAMP increases hydrolytic stability against PDE, esterases, amidases and considerably higher membrane permeability compared to cAMP .
PKI(5-24) TFA is a potent, competitive, and synthetic peptide inhibitor of PKA (cAMP-dependent protein kinase), with a Ki of 2.3 nM. PKI(5-24) TFA corresponds to residues 5-24 in the naturally occurring heat-stable protein kinase inhibitor .
Rp-cAMPS triethylammonium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependentPKA I and II (Kis of 12.5 μM and 4.5 μM, respectively) antagonist. Rp-cAMPS triethylammonium salt is resistant to hydrolysis by phosphodiesterases .
Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependentPKA I and PKA II. Sp-cAMPS is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS binds the PDE10 GAF domain with an EC50 of 40 μM .
Sp-cAMPS sodium salt, a cAMP analog, is potent activator of cAMP-dependentPKA I and PKA II. Sp-cAMPS sodium salt is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS sodium salt binds the PDE10 GAF domain with an EC50 of 40 μM .
Rp-8-CPT-cAMPS sodium, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependentPKA I and II. Rp-8-CPT-cAMPS sodium preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI .
Rp-8-CPT-cAMPS, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependentPKA I and II. Rp-8-CPT-cAMPS preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI .
Sp-cAMPS triethylamine, a cAMP analog, is potent activator of cAMP-dependentPKA I and PKA II. Sp-cAMPS triethylamine is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS triethylamine binds the PDE10 GAF domain with an EC50 of 40 μM .
Sp-8-PIP cAMP sodium is a non-corresponding isomer of 8-Piperidino-cAMP. 8-Piperidino-cAMP binds with high affinity to site A of the regulatory subunit of cAMP-dependent protein kinase type I (AI). Sp-8-PIP cAMP sodium can be used as an antagonist of cAMP-induced activation .
HA-100 dihydrochloride is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 dihydrochloride also used as a ROCK inhibitor .
HA-100 is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 also used as a ROCK inhibitor .
HA-100 hydrochloride is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 hydrochloride also used as a ROCK inhibitor .
Malantide is a synthetic dodecapeptide derived from the site phosphorylated by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide is a highly specific substrate for PKA with a Km of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts . Malantide is also an efficient substrate for PKC with a Km of 16 μM .
Sp-6-Phe-cAMPS is a potent, site-selective and membrane-permeable activator of cAMP-dependent protein kinase. Sp-6-Phe-cAMPS does not activate exchange factors directly activated by cAMP and can therefore be used as an Epac negative control. Sp-6-Phe-cAMPS can be used in the study of neurodegenerative diseases .
Malantide TFA is a synthetic dodecapeptide derived from the site phosphorylated by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide TFA is a highly specific substrate for PKA with a Km of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts . Malantide TFA is also an efficient substrate for PKC with a Km of 16 μM .
8-Benzylthio-cAMP is a derivative of cyclic adenosine monophosphate (cAMP). 8-Bn-cAMP is a site-selective activator of cAMP-dependent protein kinases. Compared with cyclic adenosine monophosphate, it is more stable to phosphodiesterase (PDE) hydrolysis and has higher membrane permeability. 8-Bn-cAMP can be used to study the role of cAMP in regulating cell proliferation, differentiation and apoptosis .
Sp-5,6-DCl-cBIMPS is a potent and specific cAMP-dependent protein kinases (cAMP-PK) activator. Sp-5,6-DCl-cBIMPS stimulates insulin release. Sp-5,6-DCl-cBIMPS inhibits U46619-induced activation of Rho, Gq and G12/G13 in platelets .
RG 14921, a compound structurally related to erbstatin, was investigated for its mechanism of inhibition of epidermal growth factor (EGF) receptor tyrosine kinase and CAMP-dependent kinase activity by kinetic analysis. Both compounds are slow-binding inhibitors of EGF receptor kinase. Erbstatin inhibits EGF receptor kinase as a partially competitive inhibitor relative to ATP and peptide substrates, suggesting that it binds at different positions in the enzyme's ATP- and peptide substrate-binding sites, thereby reducing the enzyme's binding affinity for both substrates. In contrast, the derivative RG 14921 inhibits EGF receptor kinase activity as a noncompetitive inhibitor relative to ATP and peptide substrates. Structurally related compounds exhibit different modes of inhibition, suggesting that the catalytic center of the receptor kinase domain may have a dynamic and possibly extended structure. Erbstatin and RG 14921 exerted similar effects on CAMP-dependent protein kinase activity. In this system, both compounds exhibited strong inhibition and acted in a competitive inhibition manner with ATP and a noncompetitive inhibition manner with peptide substrates.
Sp-5,6-DCl-cBIMPS sodium is a potent and specific cAMP-dependent protein kinases (cAMP-PK) activator. Sp-5,6-DCl-cBIMPS sodium stimulates insulin release. Sp-5,6-DCl-cBIMPS sodium inhibits U-46619 (HY-108566)-induced activation of Rho, Gq and G12/G13 in platelets .
Bucladesine calcium salt (Dibutyryl-cAMP calcium salt;DC2797 calcium salt) is a cell-permeable cyclic AMP (cAMP) analog and selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine calcium salt acts as a phosphodiesterase (PDE) inhibitor.
GEM231 sodium is an 18mer antisense oligonucleotide targeting the mRNA of the PKA-I (RIα regulatory subunit of cAMP dependent protein kinase type I ). GEM231 sodium induces cell growth arrest, apoptosis, and differentiation in a variety of cancer cell lines in vitro and in tumors in vivo.
GEM231 is an 18mer antisense oligonucleotide targeting the mRNA of the PKA-I (RIα regulatory subunit of cAMP dependent protein kinase type I ). GEM231 induces cell growth arrest, apoptosis, and differentiation in a variety of cancer cell lines in vitro and in tumors in vivo.
8-CPT-cAMP-AM is a highly membrane-permeant analogue of signal molecule cAMP. 8-CPT-cAMP-AM is an activator of cAMP- and cGMP-dependent protein kinases and of Epac (exchange protein activated by cAMP) .
PKI 14-22 amide,myristoylated is a potent cAMP-dependent PKA inhibitor. PKI 14-22 amide,myristoylated reduces the IgG-mediated phagocytic response and also inhibits neutrophil adhesion .
PKI 14-22 amide,myristoylated TFA is a potent cAMP-dependent PKA inhibitor. PKI 14-22 amide,myristoylated TFA reduces the IgG-mediated phagocytic response and also inhibits neutrophil adhesion .
PKA Inhibitor Fragment (6-22) amide TFA is an inhibitor of cAMP-dependentprotein kinase A (PKA), with a Ki of 2.8 nM. PKA Inhibitor Fragment (6-22) amide TFA can significantly reverse antinociceptive tolerance in mice .
PKI(5-24) is a potent, competitive, and synthetic peptide inhibitor of PKA (cAMP-dependent protein kinase), with a Ki of 2.3 nM. PKI(5-24) corresponds to residues 5-24 in the naturally occurring heat-stable protein kinase inhibitor .
PKI (5-24),amide (IP20-amide) is a 20-residue peptide that corresponds to the active portion of the heat-stable inhibitor protein of cAMP-dependent protein kinase. PKI (5-24),amide is a potent cAMP-dependent protein kinase (PKA) (PKA) inhibitor with a Ki of 2.3 nM .
PKA Inhibitor Fragment (6-22) amide is an inhibitor of cAMP-dependentprotein kinase A (PKA), with a Ki of 2.8 nM. PKA Inhibitor Fragment (6-22) amide can significantly reverse low-level morphine antinociceptive tolerance in mice .
Kemptide (amide) is a heptapeptide with properties of a cytophilic substrate. Kemptide is a molecule preserving cell membrane intactness, is phosphorylated by PKI, the inhibitory protein specific for cAMP-dependent protein kinase (PK) .
PKI(5-24) TFA is a potent, competitive, and synthetic peptide inhibitor of PKA (cAMP-dependent protein kinase), with a Ki of 2.3 nM. PKI(5-24) TFA corresponds to residues 5-24 in the naturally occurring heat-stable protein kinase inhibitor .
Malantide is a synthetic dodecapeptide derived from the site phosphorylated by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide is a highly specific substrate for PKA with a Km of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts . Malantide is also an efficient substrate for PKC with a Km of 16 μM .
Malantide TFA is a synthetic dodecapeptide derived from the site phosphorylated by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide TFA is a highly specific substrate for PKA with a Km of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts . Malantide TFA is also an efficient substrate for PKC with a Km of 16 μM .
The PKI-β protein emerged as an extremely potent competitive inhibitor of cAMP-dependent protein kinase activity. This protein operates at the molecular level, binding to the catalytic subunit of the enzyme after cAMP induces dissociation of its regulatory chain. PKI-beta Protein, Human (His) is the recombinant human-derived PKI-beta protein, expressed by E. coli , with N-6*His labeled tag.
PKA/PRKACA Protein, Canine (His) is the recombinant canine-derived PKA/PRKACA protein, expressed by E. coli , with N-His labeled tag. The total length of PKA/PRKACA Protein, Canine (His) is 349 a.a., with molecular weight of 41.51 kDa.
ATF1 Protein, Human (His) expressed in E. coli with a His tag. ATF1 is a member of the ATF/CREB family of transcription factors (TFs), specifically interacting with the consensus ATF/CRE site ‘TGACGTCA’.
PKACα protein is a key kinase that phosphorylates a variety of substrates, including CDC25B, ABL1, NFKB1, and VASP, affecting a variety of cellular processes, such as cell cycle progression, platelet regulation, and adipogenic differentiation. It also negatively regulates mTORC1 through RPTOR phosphorylation, thereby modulating signaling networks. PKACα Protein, Human (Sf9, GST) is the recombinant human-derived PKACα protein, expressed by Sf9 insect cells , with GST tagged. The total length of PKACα Protein, Human (Sf9, GST) is 350 a.a., .
PRKAR1A protein is a regulatory subunit of cAMP-dependent protein kinase that mediates cellular responses to cAMP signaling.The inactive holoenzyme has two regulatory chains and two catalytic chains.PRKAR1A Protein, Mouse (sf9, His) is the recombinant mouse-derived PRKAR1A protein, expressed by Sf9 insect cells , with C-His labeled tag.
PRKX; cAMP-dependent protein kinase catalytic subunit PRKX; PrKX; Protein kinase X; Protein kinase X-linked; Serine/threonine-protein kinase PRKX; Protein kinase PKX1
PRKX is an important serine/threonine kinase that mediates cAMP signaling and phosphorylates targets such as CREB, SMAD6, and PKD1. It regulates myeloid cell differentiation through SMAD6 phosphorylation, promotes nephrogenesis by enhancing renal epithelial cell migration and tubulogenesis, and actively promotes angiogenesis by affecting endothelial cell proliferation and migration. PRKX Protein, Human (Sf9, GST) is the recombinant human-derived PRKX protein, expressed by Sf9 insect cells , with N-GST labeled tag. The total length of PRKX Protein, Human (Sf9, GST) is 358 a.a., .
PRKAR2A; PKR2; PRKAR2; cAMP-dependent protein kinase type II-alpha regulatory subunit
WB, IHC-P, ICC/IF, IP
Human, Mouse, Rat, Pig
Phospho-PKA RII alpha (Ser99) Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 46 kDa, targeting to Phospho-PKA RII alpha (Ser99). It can be used for WB,IHC-P,ICC/IF,IP assays with tag free, in the background of Human, Mouse, Rat, Pig.
PRKACA/PRKACB; PRKACA + PRKACB; PKA alpha + beta; PKA alpha; PKA beta; cAMPdependent protein kinase alpha catalytic subunit; cAMPdependent protein kinase beta catalytic subunit; cAMPdependent protein kinase catalytic subunit alpha; cAMPdependent protein kinase catalytic subunit beta; DKFZp781I2452; MGC102831; MGC41879; MGC48865; MGC9320; PKA C alpha; PKA C beta; PKACA; PKACB; PRKACA; PRKACB; Protein kinase A catalytic subunit alpha; Protein kinase A catalytic subunit; Protein kinase A catalytic subunit beta; Protein kinase cAMPdependent catalytic alpha; Protein kinase cAMPdependent catalytic beta; cAMPdependent protein kinase catalytic subunit alpha isoform 1; cAMP-dependent protein kinase catalytic subunit alpha; KAPCA_HUMAN; KAPCB_HUMAN; PKA C alpha; PKA C-alpha; PKACA; PRKACA; Protein kinase A catalytic subunit; Protein kinase cAMPdependent catalytic alpha.
WB, ELISA, IHC-P, IHC-F, ICC/IF
Human, Mouse
PKA alpha + beta Antibody is an unconjugated, approximately 40 kDa, rabbit-derived, anti-PKA alpha + beta polyclonal antibody. PKA alpha + beta Antibody can be used for: WB, ELISA, IHC-P, IHC-F, ICC, IF expriments in human, mouse, and predicted: rat background without labeling.
Phospho-ATF2 (Thr71) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 55 kDa, targeting to Phospho-ATF2 (Thr71). It can be used for WB,ICC/IF,IP assays with tag free, in the background of Human, Mouse.
ATF2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 52 kDa, targeting to ATF2. It can be used for WB assays with tag free, in the background of Human, Mouse, Rat.
PRKACG; cAMP-dependent protein kinase catalytic subunit gamma; PKA C-gamma
WB, IP
Human, Mouse, Rat
PKA C gamma Antibody (YA1726) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1726), targeting PKA C gamma, with a predicted molecular weight of 40 kDa (observed band size: 40 kDa). PKA C gamma Antibody (YA1726) can be used for WB, IP experiment in human, mouse, rat background.
ATF1 Antibody (YA3136) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3136), targeting ATF1, with a predicted molecular weight of 29 kDa (observed band size: 36 kDa). ATF1 Antibody (YA3136) can be used for WB, ICC/IF, IP experiment in human background.
ATF5 Antibody (YA2184) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2184), targeting ATF5, with a predicted molecular weight of 31 kDa (observed band size: 31 kDa). ATF5 Antibody (YA2184) can be used for WB, IHC-P, IP experiment in human, mouse, rat background.
ATF7 Antibody (YA2651) is a biotin-conjugated non-conjugated IgG antibody, targeting ATF7, with a predicted molecular weight of 52 kDa (observed band size: 52 kDa). ATF7 Antibody (YA2651) can be used for WB experiment in human, mouse, rat background.
PRKAR1A; PKR1; PRKAR1; TSE1; cAMP-dependent protein kinase type I-alpha regulatory subunit; Tissue-specific extinguisher 1; TSE1
WB
Human, Rat
PKA RI alpha Antibody (YA1751) is a biotin-conjugated non-conjugated IgG antibody, targeting PKA RI alpha, with a predicted molecular weight of 43 kDa (observed band size: 43 kDa). PKA RI alpha Antibody (YA1751) can be used for WB experiment in human, rat background.
GEM231 sodium is an 18mer antisense oligonucleotide targeting the mRNA of the PKA-I (RIα regulatory subunit of cAMP dependent protein kinase type I ). GEM231 sodium induces cell growth arrest, apoptosis, and differentiation in a variety of cancer cell lines in vitro and in tumors in vivo.
GEM231 is an 18mer antisense oligonucleotide targeting the mRNA of the PKA-I (RIα regulatory subunit of cAMP dependent protein kinase type I ). GEM231 induces cell growth arrest, apoptosis, and differentiation in a variety of cancer cell lines in vitro and in tumors in vivo.
Inquiry Online
Your information is safe with us. * Required Fields.
